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We present an institutional experience on the clinical implementation of magnetic 
resonance (MR)-guided vaginal brachytherapy using commercially available solid 
applicator models. To test the fidelity of solid applicator models to digitize vaginal 
cylinder applicators, three datasets were evaluated. The first included 15 patients who 
were simulated with CT alone. Next, a water phantom was used to evaluate vaginal 
cylinders ranging from 20 to 35 mm in diameter with CT and MR. Finally, three 
patients undergoing HDR brachytherapy with vaginal cylinders that were simulated 
with both CT and MR were evaluated. In these assessments, the solid applicator 
models were aligned based on the outline of the applicators on the corresponding 
volumetric image, and deviations between the central source positions defined based 
on X-ray markers (on CT) and solid applicator models (on CT and MR), and the 
percent dose difference between select reference points were calculated. The mean 
central source deviation defined based on X-ray markers (on CT) and solid applicator 
models (on CT and MR) for the 15-patient cohort, the phantom, and the 3-patient 
cohort is 0.6 mm, 0.6 mm, and 1.2 mm, respectively. The average absolute percent 
dose difference for the bladder, rectum, prescription, and inferior reference points 
were 2.2%, 2.3%, 2.2%, and 2.4%, respectively, for the 15 patient cohort. For the 
phantom study, the average, absolute percent dose difference for the prescription 
and inferior reference points are 2.0% and 2.1% for the CT, 2.3% and 2.2% for the 
T1W, and 2.8% and 3.0% for the T2W images. For the three patient cohort, the 
average absolute percent dose difference for the bladder, rectum, prescription, and 
inferior reference points are 2.9%, 2.6%, 3.0%, and 4.2% for the CT, 6.5%, 1.6%, 
2.5%, and 4.7% for the T1W, and 6.0%, 7.4%, 2.6, and 2.0% for the T2W images. 
Based on the current study, aligning the applicator model to MR images provides a 
practical, efficient approach to perform MR-based brachytherapy planning. 
PACS numbers: 87.53.Jw, 87.61.Tg
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I. INTRODUCTION
Endometrial carcinoma is the most prevalent gynecological cancer in the United States and 
accounts for 6% of all cancers in females.(1) Most cancers are detected at an early stage and 
the long-term prognosis is excellent. Currently, postoperative vaginal brachytherapy, with or 
without external beam radiation therapy, is one of the main components of endometrial can-
cer treatment. Based on the Postoperative Radiation Therapy for Endometrial Carcinoma-2 
(PORTEC-2) study of early-stage postoperative endometrial cancer patients, similar results in 
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preventing distal metastasis and local recurrences were observed with patients receiving external 
beam radiation therapy as with brachytherapy alone.(2) However, it has been shown that patients 
who received brachytherapy alone develop less gastrointestinal complications and, in general, 
vaginal cylinder brachytherapy may provide better quality of life outcomes, in comparison to 
external beam radiation therapy.(3-5)
Broadly speaking, the aim of radiotherapy is to maximize the dose received by a specific 
region of interest while minimizing the dose to the surrounding normal structures. To achieve 
this end with brachytherapy, the dwell positions and times of the radioactive source(s) needs 
to be optimized. Traditionally, treatment planning for vaginal brachytherapy has relied on 
radiographs and the presence of an X-ray marker for source channel localization and digitiza-
tion (known as applicator reconstruction). However, radiographs do not provide sufficient soft-
tissue contrast to visualize the targeted tissue due to limited differences in attenuation between 
the tumor and surrounding normal tissue. As a result, traditional treatment plans have been 
designed to deliver the prescribed dose to a specific point relative to the applicator geometry 
to which anatomic significance is attached (e.g., for cervical cancer, dose has traditionally been 
prescribed to Point A(6)). 
Over the past decade, volumetric imaging has largely replaced 2D imaging for support of 
brachytherapy treatment planning.(7) Unlike radiographs, volumetric images support some visu-
alization of tumors and adjacent normal soft tissues. The Groupe Européen de Curiethérapie — 
European Society for Radiotherapy & Oncology (GEC-ESTRO) has recognized the importance 
of volumetric imaging, in particular magnetic resonance (MR) imaging (MRI), and 3D treatment 
planning for cervical cancer, and has published a series of recommendations(8-11) to assist in 
the standardization of volume and MR-based treatment planning for cervical cancer. However, 
similar recommendations are not currently available for endometrial cancer. Clinically, the use 
of MRI in the planning of vaginal brachytherapy enables detailed evaluation of the vaginal cuff, 
in addition to assessing dose delivered to clinically relevant anatomic structures of the pelvis, 
that may be important for sexual and/or pelvic floor dysfunction.   
With the introduction of MRI simulators in radiotherapy departments, there is a need for 
further guidance on the commissioning and clinical implementation of MR-guided brachy-
therapy. This manuscript serves to present an institutional experience on applicator and imag-
ing commissioning, as well as clinical implementation of MR-guided vaginal brachytherapy. 
 
II. MATERIALS AND METHODS
To clinically commission the use of MR-guided brachytherapy for vaginal cylinders, commer-
cially available standard and segmented vaginal cylinders (Varian Medical Systems, Palo Alto, 
CA) were scanned using computed tomography (CT) and MR imaging systems. Computed 
tomography scans were acquired using a 16-slice CT scanner (Royal Philips Electronics, 
Eindhoven, The Netherlands) with 1 mm slice thickness. MR scans were performed using a 3T 
wide-bore MRI simulator (Skyra, Siemens Medical Systems, Erlangen, Germany). The follow-
ing MRI sequences were used: 3D T2-weighted (SPACE) coronal (FOV: 320 × 320 × 176 mm, 
voxel size: 0.94 × 0.94 × 1 mm, TR/TE: 1700/88 ms), and 3D T1-weighted (MPRAGE) coronal 
(FOV: 300 × 300 × 166.4 mm, voxel size: 1.17 × 1.17 × 1.3 mm, TR/TE/TI: 1900/2.35/900 
ms, flip angle: 9°). The MRI simulator is outfitted with a laser marking system (LAP Laser, 
Luneburg, Germany) and detachable couch.(12) The couch supports imaging, as well as treat-
ment of brachytherapy patients, eliminating the need to transfer patients, thus reducing the 
risk of inadvertently modifying the local geometry of the applicator and surrounding tissues.
Three datasets were analyzed to aid in the commissioning of MR-guided vaginal cylinder 
brachytherapy. The first dataset was from 15 patients who underwent vaginal brachytherapy 
and were simulated with CT alone. The second dataset was a series of phantom scans of the 
standard and segmented vaginal cylinders ranging in diameter from 20 mm to 35 mm. In this 
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assessment, all applicators were simulated in a gadolinium-doped water phantom using CT and 
MR imaging. The third dataset came from three patients undergoing HDR brachytherapy with 
vaginal cylinders who were simulated with both CT and MR. The in vivo scans were acquired 
with patients positioned supine with their legs straight. 
Prior to each of the treatment planning simulations, a marker was inserted into the center of 
the applicator to assist with the visualization and digitization of the applicator tip and source 
path in the treatment planning software. For CT simulation, a commercial X-ray marker was 
utilized (Varian Medical System, Palo Alto, CA). Figure 1(a) shows a sample CT scan of a 
26 mm diameter standard vaginal cylinder applicator with an X-ray marker in place. For MR 
simulation, an in-house MR marker was made using a thin (1.168 mm outer diameter), hollow 
nylon tube (Best Medical International, Springfield, VA) filled with gadolinium-doped water 
(T1 contrast) or either water or 0.25% Agarose Gel (T2 contrast), then sealed. Agarose gel was 
added to increase the viscosity of water and reduce the mobility of the fluid in the tube. Once the 
tubes were filled, several different techniques were tested to seal the catheters. Figures 1(b) and 
1(c) show representative MR images acquired with 3D T1-weighted (T1W) and T2-weighted 
imaging sequences as detailed above. 
For treatment planning purposes, the CT and MR images were imported into a commercial 
treatment planning system (BrachyVision 8.11, Varian Medical Systems) which allows the user 
to identify the tip of the applicator, the position of the applicator/potential source positions, and 
the relevant patient anatomy. All clinical treatment plans were generated using the CT images. 
The proximal 100 mm of the applicator was digitized in the conventional manner based on the 
location of the X-ray marker. Since the desired treatment length was the proximal 40 mm of 
the applicator, to ensure adequate dose coverage, the first 50 mm of the applicator (10 dwell 
positions, with a 5 mm step size) contained active dwell positions. Once the applicator channel 
was digitized, reference points were added to monitor the dose to a nominal prescription point 
(applicator surface at  one-half of the total treatment length as defined by the authorized user 
(AU) physician), an inferior reference point (applicator surface at a distance equivalent to the 
total treatment length from the apex of the vaginal cylinder), and the ICRU 38-defined(6) bladder 
and rectum points (only for clinical plans). Treatment plans for the phantom scans were gener-
ated to deliver a total of 12 Gy over 2 fractions to the prescription point. The clinical treatment 
plans for the three-patient cohort were generated in a similar manner. However, since the initial 
prescription point for the 15-patient cohort varied between surface and a depth of 5 mm due to a 
change in clinical practice, plans that were prescribed to a depth of 5 mm were retrospectively 
renormalized to deliver 12 Gy over 2 fractions to the surface of the vaginal cylinder.   
In a retrospective analysis, applicator digitization on MR images using the in-house MR 
markers were evaluated by registering the T1W and T2W MR images to the CT images based 
on visually aligning the images to the perimeter of the vaginal applicator. The registration was 
evaluated in the para-axial, paracoronal, and parasagittal planes. Due to possible movement 
between scans, as well as possible systematic differences in the localization of markers from 
the MR scans acquired with different scanning sequences, the T1W and T2W images were 
separately aligned to the corresponding CT images.
To validate the commercially available solid applicator models in the treatment planning 
system (BrachyVision 8.11), we examined the accuracy of applicator reconstruction in CT for 
phantom and in vivo scans by comparing the digitization with our conventional technique, uti-
lizing X-ray markers. The library consists of a series of applicator models designed and made 
available by the vendor (Varian Medical Systems) for a number of commercial brachytherapy 
applicators, including vaginal cylinders. The applicator models were derived from the original 
computer-aided design (CAD) drawings of the applicators (D. Harrington, Varian Medical 
Systems, personal communication, April 13, 2015). To test the fidelity of this digitization 
technique for the 15-patient cohort and the phantom datasets, the solid applicator models were 
aligned based on the outline of the applicators on the corresponding volumetric images. The 
source position coordinates, as well as the calculated doses to the prescription and inferior 
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points, were extracted and compared with those values determined based on the digitization 
using the X-ray marker (our conventional applicator reconstruction technique). 
Once validated, the solid applicator model was evaluated for applicator reconstruction 
using MR images. The accuracy of application reconstruction in MR images was assessed 
in a gadolinium-doped water phantom study for standard and segmented vaginal cylinders. 
Similar to the validation study, applicator reconstruction based on the X-ray marker in CT was 
considered our gold standard. Thus, to evaluate the source position accuracy, the central source 
position defined based on the solid applicator model in MR was compared to that defined by 
the X-ray marker on CT. 
To demonstrate the feasibility of using the solid applicator approach in vivo for MR-based 
applicator digitization, MR and CT images were acquired for a three-patient cohort undergoing 
vaginal cylinder HDR brachytherapy treatments. This analysis was limited to three patients 
due to limited staff and equipment resources, as well as patient discomfort and inconvenience. 
Fig. 1. Coronal view of a patient with a 26 mm standard vaginal cylinder on (a) CT, (b) 3D T1W (MPRAGE) MR, and 
(c) 3D T2W (SPC) MR. To assist with the visualization of the central source channel, the appropriate marker (X-ray for 
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The central source position defined by the solid applicator model on MR was compared to the 
coordinates defined using the X-ray marker on CT. Additionally, the calculated dose to refer-
ence points of interests was also compared between the applicator reconstruction techniques.
 
III. RESULTS 
A summary of the distributions of central source positions defined by the conventional applicator 
reconstruction method versus the CT-aligned solid applicator model for the 15-patient cohort is 
presented in Table 1. The mean source position deviation across the 15 patients is 0.6 mm and 
the average absolute percent dose difference for the bladder, rectum, prescription, and inferior 
reference points are 2.2%, 2.3%, 2.2%, and 2.4%, respectively.
Figure 2 shows sample CT and MR (T1W and T2W) images of a 30 mm standard vaginal 
cylinder in a gadolinium-doped water phantom in paracoronal planes relative to the applicator. 
Table 1. Magnitude of source displacement for the central source position and percent dose difference at reference 
points when applicator reconstruction based on the solid applicator model is compared to reconstruction based on X-ray 
markers over the range of 10 dwell positions for 15 different patients simulated with CT alone.
        % Dose
       % Dose Difference 
       Difference Inferior % Dose % Dose
 Subject Applicator Min Max Mean SD Prescription Reference Difference Difference
 Number Type (mm) (mm) (mm) (mm) Point Point Bladder Rectum
 1 Standard  3.0 cm 0.8 1.0 0.9 0.1 4.6 3.2 1.2 -0.6
 2 Standard  2.6 cm 0.1 0.5 0.3 0.1 -0.8 -0.2 -0.5 -0.1
 3 Standard  3.0 cm 0.9 1.0 1.0 0.0 1.5 -0.4 -4.4 5.3
 4 Standard  3.5 cm 0.4 0.5 0.5 0.0 -1.1 0.1 -0.6 -1.5
 5 Standard  2.0 cm 0.4 0.6 0.5 0.1 -6.3 -7.2 N/A 3.5
 6 Standard  3.0 cm 0.6 0.8 0.7 0.1 -2.8 -3.1 -2.7 2.7
 7 Standard  3.0 cm 0.6 0.8 0.7 0.1 -2.1 -0.6 -2.9 1.9
 8 Segmented  2.6 cm 0.5 0.9 0.7 0.1 1.0 -0.3 N/A -2.0
 9 Standard  3.5 cm 0.3 0.5 0.4 0.0 0.9 -8.5 1.4 -1.7
 10 Segmented  3.0 cm 0.5 0.7 0.6 0.0 -1.4 -4.9 -2.6 2.6
 11 Standard  3.0 cm 0.4 0.6 0.5 0.1 1.3 0.5 2.1 -1.3
 12 Standard  2.6 cm 0.6 0.9 0.8 0.1 -2.3 -2.1 4.0 -0.8
 13 Segmented  2.6 cm 0.1 0.4 0.3 0.1 -2.7 -1.5 0.8 -3.6
 14 Segmented  3.5 cm 0.4 0.8 0.6 0.1 -1.8 0.0 2.9 -3.7
 15 Segmented  2.6 cm 0.6 0.7 0.6 0.0 2.6 3.5 2.7 -3.4
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The vaginal applicator appears hypo-intense on both MR image sets, and the source path is 
visible when an MR marker with the appropriate contrast agent was placed in the applicator 
prior to simulation. However, due to difficulties obtaining a water-tight seal, this marker could 
not be made reproducibly, resulting in displacements of the visualized applicator tip. Similar 
results were observed clinically for the three-patient cohort and, as a result, we discontinued 
the use of the MR marker in favor of the solid applicator models for applicator digitization. 
Figure 3 shows sample CT, T1W and T2W MR images of a 30 mm standard vaginal cyl-
inder in a gadolinium-doped water phantom in paracoronal planes relative to the applicator 
Fig. 2. A paracoronal view of the CT (left), T1W (middle), and T2W (right) images of a 30 mm standard vaginal applicator 
with the appropriate CT or MR marker. In contrast to the CT, the MR markers for both the T1W and T2W images were 
displaced from the tip of the applicator, suggesting the markers were compromised.
Fig. 3. (Top row) Paracoronal view of the CT (left), T1W (middle), and T2W (right) images of the 30 mm standard vaginal 
cylinder with the appropriate marker in place. (Middle row) Applicator reconstruction using X-ray markers on CT and 
overlaid on the MR images after the MR images were registered with the CT. (Bottom row) Applicator reconstruction 
using the solid applicator model aligned independently in each imaging modality. 
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with an overlay of the solid applicator model (in red) with the appropriate applicator diameter. 
A summary of the distributions of differences in central source positions defined based on the 
X-ray marker on CT and the solid applicator models on CT and MR, as well as the percent 
dose difference for the prescription and inferior reference points, is shown in Table 2. The mean 
source position deviation for the segmented cylinders is 0.4 mm, 0.9 mm, and 0.6 mm for the 
CT, T1W, and T2W images, respectively. The average, absolute percent dose difference for 
the prescription and inferior reference points are 1.3% and 1.3% for the CT, 2.6% and 2.0% 
for the T1W, and 2.2% and 3.1%, respectively, for the T2W images. The mean source position 
deviation for the standard vaginal cylinders is 0.5 mm, 0.5 mm and 0.8 mm for the CT, T1W, 
and T2W images, respectively. The average absolute percent dose difference for prescription 
and inferior reference points are 2.5% and 2.7% for the CT, 2.1% and 2.3 % for the T1W, and 
3.2% and 2.9% for the T2W images.
For the last dataset, the three-patient cohort, a summary of the differences in central source 
positions based on the conventional digitization technique, as well as the percent dose differ-
ence for the bladder, rectum, prescription, and inferior reference point, is presented in Table 3. 
The mean source position deviation for all three patients is 0.9 mm, 1.2 mm, and 1.4 mm for 
the CT, T1W, and T2W images, respectively. The average absolute percent dose difference 
Table 2. Magnitude of central source deviations and percent dose differences for a series of commercially available 
standard and segmented vaginal cylinders scanned in a water phantom. The cylinders were digitized with a commercial 
solid applicator model, as well as the conventional method of applicator reconstruction, based on an X-ray marker in CT.
        % Dose 
       % Dose Difference
       Difference Inferior
   Min Max Mean SD Prescription Reference
   (mm) (mm) (mm) (mm) Point Point
  Solid CT vs. X-ray marker 0.4 0.5 0.4 0.0 -2.2 -1.6
 Segmented 2.0 cm Solid T1W vs. X-ray marker 0.4 0.6 0.5 0.1 -2.9 -1.7
  Solid T2W vs. X-ray marker 0.3 0.7 0.5 0.1 2.6 3.4
  Solid CT vs. X-ray marker 0.5 0.7 0.6 0.1 -0.3 0.8
 Segmented 2.6 cm Solid T1W vs. X-ray marker 0.9 1.1 1.0 0.0 1.1 3.0
  Solid T2W vs. X-ray marker 0.5 0.5 0.5 0.0 2.8 3.7
  Solid CT vs. X-ray marker 0.3 0.5 0.4 0.1 2.2 2.9
 Segmented 3.0 cm Solid T1W vs. X-ray marker 0.5 0.9 0.6 0.1 0.5 2.6
  Solid T2W vs. X-ray marker 0.4 0.7 0.5 0.1 2.5 3.7
  Solid CT vs. X-ray marker 0.2 0.4 0.3 0.1 -0.6 0.0
 Segmented 3.5 cm Solid T1W vs. X-ray marker 1.3 2.0 1.6 0.2 -5.8 0.6
  Solid T2W vs. X-ray marker 0.9 1.0 1.0 0.1 -0.8 1.5
  Solid CT vs. X-ray marker 0.2 0.3 0.3 0.0 -2.3 -2.4
 Standard 2.0 cm Solid T1W vs. X-ray marker 0.2 0.3 0.3 0.0 -0.7 -0.2
  Solid T2W vs. X-ray marker 0.5 0.7 0.6 0.0 2.3 3.7
  Solid CT vs. X-ray marker 0.5 0.5 0.5 0.0 4.9 5.6
 Standard 2.3 cm Solid T1W vs. X-ray marker 0.5 0.6 0.6 0.0 -0.7 0.5
  Solid T2W vs. X-ray marker 0.5 1.0 0.7 0.1 5.0 1.5
  Solid CT vs. X-ray marker 0.2 0.5 0.4 0.1 -0.8 0.2
 Standard 2.6 cm Solid T1W vs. X-ray marker 0.4 0.5 0.5 0.0 -2.1 -1.8
  Solid T2W vs. X-ray marker 0.5 0.7 0.6 0.0 -1.7 -2.2
  Solid CT vs. X-ray marker 0.3 0.5 0.4 0.1 3.5 3.4
 Standard 3.0 cm Solid T1W vs. X-ray marker 0.4 0.5 0.5 0.1 4.4 4.7
  Solid T2W vs. X-ray marker 0.3 0.8 0.5 0.1 4.7 4.2
  Solid CT vs. X-ray marker 0.6 0.8 0.7 0.0 1.0 2.1
 Standard 3.5 cm Solid T1W vs. X-ray marker 0.8 1.0 0.9 0.1 2.8 4.2
  Solid T2W vs. X-ray marker 1.5 1.7 1.6 0.1 -2.4 2.7
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for the bladder, rectum, prescription, and inferior reference points are 2.9%, 2.6%, 3.0%, and 
4.2% for the CT, 6.5%, 1.6%, 2.5%, and 4.7% for the T1W, and 6.0%, 7.4%, 2.6%, and 2.0%, 
respectively, for the T2W images.   
 
IV. DISCUSSION
Recommendations and guidelines for image-guided brachytherapy for gynecological malig-
nancies have mainly focused on the treatment of cervical cancers;(8-11,13-22) there are limited 
studies(23-27) discussing image-guided vaginal cylinder brachytherapy for post-surgery endo-
metrial carcinoma. CT is the most common imaging modality for 3D based image-guided 
vaginal cylinder brachytherapy. It has been used to assess air gaps at the apex of the vagina,(26) 
the effect of bladder filling,(25,27) to perform dose–volume histogram (DVH) analyses,(24) and 
the effect of single versus multichannel cylinder in high-dose-rate brachytherapy of vaginal 
cuff.(23,28) However, with the increased accessibility of MR imaging and its superior soft-tissue 
contrast, there has been an increase in its usage for brachytherapy treatment planning and treat-
ment response evaluation. We have recently presented preliminary data from our institution 
suggesting that based on T2W MR images, the vaginal cuff is underdosed in over half of our 
patients due to limitations in the design of the standard vaginal cylinders and/or changes in 
surgical practices.(29) Efforts of other groups at creating custom mold applicators constructed 
with 3D printers(30,31) further demonstrate the emerging need for more precise, tissue-directed 
planning for vaginal brachytherapy.
In this study, we share our experience with the clinical implementation of MR-guided 
brachytherapy, which allows for simulation and planning of vaginal cylinder brachytherapy 
patients based solely on MR imaging. Applicator reconstruction is an important part of this 
process. There have been several proposed methods for applicator reconstruction using MR 
images including the use of an MR compatible marker(32,33) and an applicator library.(13,34) Each 
Table 3. Magnitude of source displacement of the central source position and percent dose difference at reference 
points when applicator reconstruction based on the solid applicator model is compared to reconstruction based on 
X-ray markers for three different patients.
        %Dose
       %Dose Difference
      Std. Difference Inferior %Dose %Dose
   Min Max Mean Dev. Prescription Reference Difference Difference
   (mm) (mm) (mm) (mm) Point  Point Bladder Rectum
  Solid CT vs.  0.5 1.1 0.8 0.2 2.9 4.2 -4.8 3.0
Patient 1 X-ray marker
 Standard T1W vs. 
 2.6 cm X-ray marker 
0.5 0.8 0.6 0.1 1.6 3.2 -4.0 2.9
  T2W vs.
  X-ray marker 0.7 0.9 0.8 0.0 -3.4 -2.8 1.8 1.0
  Solid CT vs.
 Patient 2 X-ray marker 
1.2 1.3 1.2 0.0 5.3 7.8 -0.1 -4.5
 Standard T1W vs.
 2.6 cm X-ray marker 
1.0 1.3 1.1 0.1 -0.2 2.9 -3.1 0.7
  T2W vs.
  X-ray marker 1.6 2.5 2.0 0.3 -4.1 -1.6 11.3 -13.9
  Solid CT vs.
 Patient 3 X-ray marker 
0.5 0.8 0.7 0.1 0.7 -0.6 -3.7 -0.3
 Standard T1W vs.
 3.0 cm X-ray marker 
1.6 1.9 1.7 0.1 5.9 8.0 -12.5 -1.1
  T2W vs.
  X-ray marker 1.3 2.0 1.6 0.2 0.2 -1.8 -4.8 -7.3
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of these methods have known limitations, such as the limited availability of commercial MR 
compatible markers, difficulties fabricating leak-tight MR markers, and limits to the available 
applicators for which vendors have provided  applicator models. 
At our institution, we began investigating applicator reconstruction on MR images by using 
in-house MR-visible markers for both T1W and T2W MR images. However, as demonstrated 
in Fig. 2, we encountered difficulties maintaining a water-tight seal of these markers. Several 
different techniques were employed to seal the catheters including a heat seal with and without 
hot glue, bone wax with cyanoacrylate, and Water Weld (JB Weld, Sulphur Springs, TX) with 
and without cyanoacrylate; however, none of these methods were successful. As such, our 
group discontinued the use of the in-house markers for applicator reconstruction. We believe 
that a commercial solution would help mitigate this issue. 
The main focus of this study was to evaluate applicator reconstruction on CT and MR images 
using solid applicator models available in a commercial treatment planning system. This was 
accomplished by retrospectively reviewing a 15-patient cohort undergoing vaginal cylinder 
brachytherapy, as well as a series of phantom scans acquired with standard and segmented 
cylinders of a variety of sizes. Our measurements lead us to believe that the solid model tech-
nique is a reliable and reproducible alternative to our conventional technique for applicator 
reconstruction (based on X-ray markers) of vaginal cylinders. A slightly larger source deviation 
was observed in vivo due to factors such as internal organ motion. The associated deviation was 
larger on MR images due largely in part to the longer scan times required for MR images (on 
average 250 s for 3D T1 MPRAGE scan, 720 s for 3D T2 Space scan, versus 10 s for a 1 mm 
slice thickness CT scan). The increase in scan time can result in degradation in the quality of 
the MR images such as artifacts and blurring due to organ and patient motion, which presents 
challenges during applicator reconstruction. As such, we have transitioned to the use of 3D 
T1W VIBE scans, which have a considerably shorter acquisition times (on the order of 90 s). 
Although antiperistalsis agents, such as glucagon, are commonly used for pelvic MR imaging 
to reduce image artifacts, especially for longer scan sequences,(35,36) due to the associated side 
effects of this medication (e.g., nausea and vomiting(37)) we have elected not to use this agent 
for brachytherapy patients. 
In this study, applicator reconstruction has been performed for vaginal cylinders with solid 
applicator models on T1W and T2W MR images from a 3T MR scanner. Once validated, this 
method of applicator reconstruction can be applied to other applicators and images acquired 
from MR scanners with other field strengths. Applicator reconstruction strategies introduced 
in this study may not be directly transferrable to other treatment planning systems, but similar 
methods, such as applicator reconstruction based on user defined library plans, may prove to 
be useful when a reliable MR marker is not available. However, it is imperative that commis-
sioning include both phantom and in vivo scans to validate the accuracy and reproducibility of 
applicator reconstruction prior to clinical implementation of MR-based brachytherapy.
 
V. CONCLUSIONS
The clinical implementation of MR-guided vaginal brachytherapy in our department has 
been described. We investigated the use of commercial solid applicator models for applicator 
reconstruction. Based on this study, the solid applicator model provides a practical approach 
to vaginal cylinder applicator reconstruction for MR-based brachytherapy planning. This will 
facilitate the transition to volume-based planning which has the added advantage of improved 
soft-tissue visualization and possible utilization of functional imaging. 
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